Abstract
Abstract
Aims
Many large-scale population-based surveys, research studies, and clinical care allow for inclusion of proxy reporting as a strategy to collect outcomes when patients are unavailable or unable to provide reliable self-report. Prior work identified an absence of methodological guidelines regarding proxy reporting in adult populations, including who can serve as a proxy, and considerations for data collection, analysis, and reporting. The primary objective of this work by the ISOQOL Proxy Task Force was to review documents and clinical outcome assessment measures with respect to proxy reporting and to develop, through consensus, considerations for proxy reporting.
Methods
We assembled an international group with clinically relevant and/or methodological expertise on proxy use in adult populations. We conducted a targeted review of documentation based on regulatory, non-regulatory, professional society, and individual measure sources. Using a standardized collection form, proxy-related information was extracted from each source including definitions of a proxy, characteristics of a proxy, domains addressable or addressed by a proxy, and observer-reporting.
Results
The definition of proxy was inconsistent across 39 sources, except regulatory documents which defined a proxy as a person other than the patient who reports on an outcome as if she/he were the patient. While proxy report was discouraged in regulatory documentation, it was acknowledged there were instances where self-report was impossible. Many documentation sources indicated proxies would be well-justified in certain contexts, but did not indicate who could act as a proxy, when proxies could be used, what domains of patient health they could report on, or how data should be reported. Observer-reported outcomes were typically defined as those based on observed behaviors, however there was not a consistent differentiation between proxy and observer reporting. Based on information extracted from these resources, we developed a checklist of considerations when including proxy-reported measures or using proxies in study design, data collection, analysis, interpretation and reporting of proxy reported data.
Conclusion
Our targeted review highlights a lack of clarity in capturing, interpreting and reporting data from proxies in adult populations. We provide a checklist of considerations to assist researchers and clinicians with including proxies in research studies and clinical care. Lastly, our review identified areas where further guidance and future research are necessary.
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference71 articles.
1. About FDA. Clinical outcome assessment (COA): frequently asked questions. https://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions. Accessed 31 Mar 2023
2. European Medicines Agency (2016) Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies. https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed 31 Mar 2023
3. U.S. Department of Health and Human Services, Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https://www.fda.gov/media/77832/download. Accessed 31 Mar 2023
4. Gliklich RE, DNA, Leavy MB (eds) (2014) Registries for evaluating patient outcomes: a user’s guide [internet]. 3rd edition. Rockville, MD: Agency for Healthcare Research and Quality (US); 2014 Apr. Report No.: 13(14)-EHC111
5. Rand SCJ (2015) Quality and outcomes of person-centred care policy research unit. Using proxies to assess quality of life: a review of the issues and challenges. https://www.pssru.ac.uk/pub/4980.pdf. Accessed 31 Mar 2023